Logo

Zavation’s eZspand Lateral Lumbar Interbody Fusion Device Receives the US FDA’s Clearance for the Treatment of Degenerative Disc Disease

Share this
Zavation’s eZspand Lateral Lumbar Interbody Fusion Device Receives the US FDA’s Clearance for the Treatment of Degenerative Disc Disease

Zavation’s eZspand Lateral Lumbar Interbody Fusion Device Receives the US FDA’s Clearance for the Treatment of Degenerative Disc Disease

Shots:

  • The company has received the US FDA 510(k) clearance for its eZspand Lateral expandable lumbar interbody fusion device
  • The device offers continual expansion to optimize the fit for each patient along with improved structural stability and sagittal balance. Additionally, patients who have completed 6mos. of non-operative treatment should utilize the device
  • In skeletally mature patients, Zavation eZspand interbody system implants are recommended for use with autogenous bone transplant in spinal fusion procedures & are designed to treat DDD with up to grade I spondylolisthesis at one or two contiguous levels in the lumbar spine from L2 to S1

Ref: PRNewswire  | Image: Zavation

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions